The estimated Net Worth of Gerard Ber is at least $2.09 Millón dollars as of 12 August 2024. Gerard Ber owns over 15,500 units of Y-Mabs Therapeutics Inc stock worth over $281,603 and over the last 5 years he sold YMAB stock worth over $1,578,413. In addition, he makes $230,843 as Independent Director at Y-Mabs Therapeutics Inc.
Gerard has made over 3 trades of the Y-Mabs Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 15,500 units of YMAB stock worth $1,495,440 on 12 August 2024.
The largest trade he's ever made was selling 15,500 units of Y-Mabs Therapeutics Inc stock on 12 August 2024 worth over $1,495,440. On average, Gerard trades about 921 units every 43 days since 2019. As of 12 August 2024 he still owns at least 21,221 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Gerard Ber stock trades at the bottom of the page.
Dr. Gerard Ber, Ph.D., is Independent Director of the Company. Dr. Ber has been a member of our Board of Directors since December 2018. Dr. Ber has more than 30 years of experience in Molecular Nuclear Medicine ("MNM") including development, production and commercialization of diagnostics and therapeutic products for several indications in oncology, cardiology, neurology and infectious/inflammatory diseases. In 2002, Dr. Ber co-founded Advanced Accelerator Applications S.A., and was its Chief Operating Officer from 2002 to 2018, when it was sold to Novartis AG. Dr. Ber grew Advanced Accelerator Applications S.A. from a start-up to a global leader in MNM and was member of its board of directors from 2002 to 2015, when Advanced Accelerator Applications S.A. listed on The Nasdaq Global Select Market. Dr. Ber currently serves on the board of Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX). He received his Ph.D. degree in Pharmacy from the Scientific and Medical University of Grenoble. Dr. Ber currently serves as a member of our Compensation Committee and our Nominating and Corporate Governance Committee.
As the Independent Director of Y-Mabs Therapeutics Inc, the total compensation of Gerard Ber at Y-Mabs Therapeutics Inc is $230,843. There are 9 executives at Y-Mabs Therapeutics Inc getting paid more, with Claus Moller-San Pedro having the highest compensation of $967,497.
Gerard Ber is 62, he's been the Independent Director of Y-Mabs Therapeutics Inc since 2018. There are 3 older and 16 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
Gerard's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON ROAD, SOUTH BUILDING, BEDFORD, MA, 01730.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad y Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: